Highlights in Diabetes and Metabolism From ASN 2022 Highlights in Diabetes and Metabolism From ASN 2022

From ASN 2022, Dr Carol Wysham highlights data on glucose-lowering drugs in patients with T2D, including empagliflozin and semaglutide, and a link between cognitive disorders and albuminuria.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news